Connectomic Biotyping Of Schizophrenia Patients

Abstract

Patients with schizophrenia differ widely in their symptoms, long-term outcome and response to medication. However, most patients are treated with the same medications and interventions. This study aims to better facilitate the targeting of novel treatments to groups of patients (biotypes) that are likely to benefit most from a treatment. Groups of patients that share distinct patterns of deficits in brain connectivity will be delineated using state-of-the-art white matter imaging techniques.